^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-A2009
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
Related drugs:
Phase 2
Fudan University
Recruiting
Last update posted :
12/10/2024
Initiation :
10/21/2024
Primary completion :
09/01/2026
Completion :
09/01/2027
HER-2 • NECTIN4 • TACSTD2
|
HER-2 expression
|
trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
Share
